A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19

DOI record: { "DOI": "10.1016/j.eclinm.2022.101310", "ISSN": [ "2589-5370" ], "URL": "http://dx.doi.org/10.1016/j.eclinm.2022.101310", "alternative-id": [ "S2589537022000402" ], "article-number": "101310", "author": [ { "affiliation": [], "family": "Rossignol", "given": "Jean-François", "sequence": "first" }, { "affiliation": [], "family": "Bardin", "given": "Matthew C.", "sequence": "additional" }, { "affiliation": [], "family": "Fulgencio", "given": "Jessica", "sequence": "additional" }, { "affiliation": [], "family": "Mogelnicki", "given": "Dena", "sequence": "additional" }, { "affiliation": [], "family": "Bréchot", "given": "Christian", "sequence": "additional" } ], "container-title": [ "eClinicalMedicine" ], "content-domain": { "crossmark-restriction": false, "domain": [] }, "created": { "date-parts": [ [ 2022, 2, 28 ] ], "date-time": "2022-02-28T10:03:26Z", "timestamp": 1646042606000 }, "deposited": { "date-parts": [ [ 2022, 2, 28 ] ], "date-time": "2022-02-28T10:03:45Z", "timestamp": 1646042625000 }, "indexed": { "date-parts": [ [ 2022, 2, 28 ] ], "date-time": "2022-02-28T10:40:55Z", "timestamp": 1646044855177 }, "is-referenced-by-count": 0, "issn-type": [ { "type": "print", "value": "2589-5370" } ], "issued": { "date-parts": [ [ 2022, 3 ] ] }, "language": "en", "license": [ { "URL": "https://www.elsevier.com/tdm/userlicense/1.0/", "content-version": "tdm", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 3, 1 ] ], "date-time": "2022-03-01T00:00:00Z", "timestamp": 1646092800000 } }, { "URL": "http://creativecommons.org/licenses/by/4.0/", "content-version": "vor", "delay-in-days": 0, "start": { "date-parts": [ [ 2022, 2, 4 ] ], "date-time": "2022-02-04T00:00:00Z", "timestamp": 1643932800000 } } ], "link": [ { "URL": "https://api.elsevier.com/content/article/PII:S2589537022000402?httpAccept=text/xml", "content-type": "text/xml", "content-version": "vor", "intended-application": "text-mining" }, { "URL": "https://api.elsevier.com/content/article/PII:S2589537022000402?httpAccept=text/plain", "content-type": "text/plain", "content-version": "vor", "intended-application": "text-mining" } ], "member": "78", "original-title": [], "page": "101310", "prefix": "10.1016", "published": { "date-parts": [ [ 2022, 3 ] ] }, "published-print": { "date-parts": [ [ 2022, 3 ] ] }, "publisher": "Elsevier BV", "reference": [ { "DOI": "10.1001/jama.2020.22813", "article-title": "Therapy for early COVID-19, a critical need", "author": "Kim", "doi-asserted-by": "crossref", "first-page": "2149", "journal-title": "JAMA", "key": "10.1016/j.eclinm.2022.101310_bib0001", "volume": "324", "year": "2020" }, { "DOI": "10.31083/j.rcm.2020.04.264", "article-title": "Multifaceted highly targeted sequential multidrug treatment of early ambulatory high-risk SARS-CoV-2 infection (COVID-19)", "author": "McCullough", "doi-asserted-by": "crossref", "first-page": "517", "journal-title": "Rev Cardiovasc Med", "key": "10.1016/j.eclinm.2022.101310_bib0002", "volume": "21", "year": "2020" }, { "key": "10.1016/j.eclinm.2022.101310_bib0003", "unstructured": "Bamlanivimab and Etesevimab Fact Sheet for Health Care Providers Emergency Use Authorization. Eli Lilly, Indianapolis, IN. Revised 03/2021. Available at: http://pi.lilly.com/eua/bam-and-ete-eua-factsheet-hcp.pdf. Accessed April 9, 2021." }, { "key": "10.1016/j.eclinm.2022.101310_bib0004", "unstructured": "REGEN-COV Fact Sheet for Health Care Providers Emergency Use Authorization. Regeneron pharmaceuticals, Inc., Tarrytown, NY. Revised 03/2021. Available at: https://www.fda.gov/media/145611/download. Accessed April 9, 2021." }, { "DOI": "10.1038/s41591-021-01294-w", "article-title": "Resistance of SARS-CoV-2 variants to neutralization by monoclonal and serum-derived polyclonal antibodies", "author": "Chen", "doi-asserted-by": "crossref", "journal-title": "Nat Med", "key": "10.1016/j.eclinm.2022.101310_bib0005", "year": "2021" }, { "DOI": "10.1016/j.antiviral.2014.07.014", "article-title": "Nitazoxanide: a first-in-class broad-spectrum antiviral agent", "author": "Rossignol", "doi-asserted-by": "crossref", "first-page": "94", "journal-title": "Antivir Res", "key": "10.1016/j.eclinm.2022.101310_bib0006", "volume": "110", "year": "2014" }, { "DOI": "10.1016/j.antiviral.2014.11.010", "article-title": "A screen of the NIH clinical collection small molecule library identifies potential anti-coronavirus drugs", "author": "Cao", "doi-asserted-by": "crossref", "first-page": "1", "journal-title": "Antivir Res", "key": "10.1016/j.eclinm.2022.101310_bib0007", "volume": "114", "year": "2015" }, { "DOI": "10.1016/j.jiph.2016.04.001", "article-title": "Nitazoxanide, a new drug candidate for the treatment of Middle East respiratory syndrome coronavirus", "author": "Rossignol", "doi-asserted-by": "crossref", "first-page": "227", "journal-title": "J Infect Public Health", "key": "10.1016/j.eclinm.2022.101310_bib0008", "volume": "9", "year": "2016" }, { "article-title": "Broad-spectrum antiviral nitazoxanide inhibits ATP-dependent replication of respiratory viruses and proinflammatory cytokines", "author": "Rossignol", "key": "10.1016/j.eclinm.2022.101310_bib0009", "series-title": "Proceedings of the 2nd International Meeting on Respiratory Pathogens", "year": "2018" }, { "DOI": "10.1016/j.intimp.2012.03.002", "article-title": "Nitazoxanide suppresses IL-6 production in LPS-stimulated mouse macrophages and TG-injected mice", "author": "Hong", "doi-asserted-by": "crossref", "first-page": "23", "journal-title": "Int Immunopharmacol", "key": "10.1016/j.eclinm.2022.101310_bib0010", "volume": "13", "year": "2012" }, { "DOI": "10.1038/s41422-020-0282-0", "article-title": "Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro", "author": "Wang", "doi-asserted-by": "crossref", "first-page": "269", "journal-title": "Cell Res", "key": "10.1016/j.eclinm.2022.101310_bib0011", "volume": "30", "year": "2020" }, { "DOI": "10.1101/2021.04.12.439201", "doi-asserted-by": "crossref", "key": "10.1016/j.eclinm.2022.101310_bib0012", "unstructured": "Riccio A, Santopolo S, Rossi A, Piacentini S., Rossignol J.F., Santoro M.G. Impairment of SARS-CoV-2 spike glycoprotein maturation and fusion activity by the broad-spectrum anti-infective drug nitazoxanide [Preprint]. bioRxiv 2021 Apr 12: 04.12.439201." }, { "DOI": "10.1016/j.ymthe.2020.12.016", "article-title": "Synergistic and antagonistic drug combinations against SARS-CoV-2", "author": "Bobrowski", "doi-asserted-by": "crossref", "first-page": "873", "issue": "2", "journal-title": "Mol Ther", "key": "10.1016/j.eclinm.2022.101310_bib0013", "volume": "29", "year": "2021" }, { "DOI": "10.3390/ph13120443", "article-title": "FDA-approved drugs with potent in vitro antiviral activity against severe acute respiratory syndrome coronavirus 2", "author": "Mostafa", "doi-asserted-by": "crossref", "first-page": "443", "issue": "12", "journal-title": "Pharmaceuticals", "key": "10.1016/j.eclinm.2022.101310_bib0014", "volume": "13", "year": "2020" }, { "DOI": "10.1101/2020.11.25.399055", "doi-asserted-by": "crossref", "key": "10.1016/j.eclinm.2022.101310_bib0015", "unstructured": "Lian E, McAlister C, Ramirez G. et al. Triple combination nitazoxanide, ribavirin, and hydroxychloroquine results in the multiplicative reduction of in vitro SARS-CoV-2 viral replication [Preprint]. bioRxiv 2020 Nov 26: 11.25.399055." }, { "DOI": "10.1074/jbc.M109.029470", "article-title": "Thiazolides, a new class of anti-influenza molecules targeting viral hemagglutinin at the post-translational level", "author": "Rossignol", "doi-asserted-by": "crossref", "first-page": "29798", "journal-title": "J Biol Chem", "key": "10.1016/j.eclinm.2022.101310_bib0016", "volume": "284", "year": "2009" }, { "DOI": "10.1038/s41598-018-28172-9", "article-title": "Nitazoxanide inhibits paramyxovirus replication by targeting the fusion protein folding: role of glycoprotein-specific thiol oxidoreductase ERp57", "author": "Piacentini", "doi-asserted-by": "crossref", "first-page": "10425", "journal-title": "Sci Rep", "key": "10.1016/j.eclinm.2022.101310_bib0017", "volume": "8", "year": "2018" }, { "DOI": "10.1128/AAC.00078-08", "article-title": "Potential for hepatitis C virus resistance to nitazoxanide or tizoxanide", "author": "Korba", "doi-asserted-by": "crossref", "first-page": "4069", "journal-title": "Antimicrob Agents Chemother", "key": "10.1016/j.eclinm.2022.101310_bib0018", "volume": "52", "year": "2008" }, { "DOI": "10.1101/2020.08.12.246389", "doi-asserted-by": "crossref", "key": "10.1016/j.eclinm.2022.101310_bib0019", "unstructured": "Risner KH, Tieu KV, Wang Y. et al. Maraviroc inhibits SARS-CoV-2 multiplication and s-protein mediated cell fusion in cell culture [Preprint]. bioRxiv 2020 Aug 13: 2020.08.12.246389." }, { "article-title": "Nitazoxanide superiority to placebo to treat moderate COVID-19 – a pilot prove of concept randomized double-blind clinical trial", "author": "Blum", "journal-title": "EClinicalMedicine", "key": "10.1016/j.eclinm.2022.101310_bib0020", "year": "2021" }, { "DOI": "10.1371/journal.pone.0194180", "article-title": "Performance of the inFLUenza patient-reported outcome (FLU-PRO) diary in patients with influenza-like illness (ILI)", "author": "Powers", "doi-asserted-by": "crossref", "journal-title": "PLoS One", "key": "10.1016/j.eclinm.2022.101310_bib0021", "volume": "13", "year": "2018" }, { "DOI": "10.1016/S1473-3099(14)70717-0", "article-title": "A randomized, double-blind, placebo controlled clinical trial of nitazoxanide in adults and adolescents with acute uncomplicated influenza", "author": "Haffizulla", "doi-asserted-by": "crossref", "first-page": "609", "journal-title": "Lancet Infect Dis", "key": "10.1016/j.eclinm.2022.101310_bib0022", "volume": "14", "year": "2014" }, { "DOI": "10.1056/NEJMoa2029849", "article-title": "SARS-CoV-2 Neutralizing antibody LY-CoV555 in outpatients with Covid-19", "author": "Chen", "doi-asserted-by": "crossref", "first-page": "229", "journal-title": "N Engl J Med", "key": "10.1016/j.eclinm.2022.101310_bib0023", "volume": "384", "year": "2021" }, { "DOI": "10.1056/NEJMoa2035002", "article-title": "REGN-COV2, a neutralizing antibody cocktail, in outpatients with Covid-19", "author": "Weinreich", "doi-asserted-by": "crossref", "first-page": "238", "journal-title": "N Engl J Med", "key": "10.1016/j.eclinm.2022.101310_bib0024", "volume": "384", "year": "2021" }, { "article-title": "Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial", "author": "Rocco", "journal-title": "Eur Respir J", "key": "10.1016/j.eclinm.2022.101310_bib0025", "volume": "14", "year": "2021" }, { "DOI": "10.1101/2021.03.03.21252509", "doi-asserted-by": "crossref", "key": "10.1016/j.eclinm.2022.101310_bib0026", "unstructured": "Silva M, Espejo AL, Pereyra M. et al. Efficacy of nitazoxanide in reducing the viral load in COVID-19 patients. Randomized, placebo-controlled, single-blinded, parallel group, pilot study [Preprint]. medRxiv 2021 Mar 5: 03.03.21252509." } ], "reference-count": 26, "references-count": 26, "relation": {}, "score": 1, "short-container-title": [ "eClinicalMedicine" ], "short-title": [], "source": "Crossref", "subject": [ "General Medicine" ], "subtitle": [], "title": [ "A randomized double-blind placebo-controlled clinical trial of nitazoxanide for treatment of mild or moderate COVID-19" ], "type": "journal-article", "volume": "45" }